Racial disparities exist in access to kidney transplantation

A new study published in the American Journal of Transplantation reveals that racial disparities exist in both the early and late steps in access to kidney transplantation. This study is part of the February special themed issue of the journal on racial disparity.

Led by Rachel E. Patzer, PhD, MPH, of the Emory Transplant Center in Atlanta, Georgia, researchers examined 2,291 adult patients referred for renal transplant evaluation at a single transplant center in the Southeastern U.S. from 2005-2007, followed through May 2010. Demographic and clinical data were assessed and Cox models were used to examine the effect of race on referral, evaluation, waitlisting, and organ receipt.

Of the 2,291 patients, 64.9% were black, the mean age was 49.4 years, and 33.6% lived in poor neighborhoods.

Racial disparities were observed in access to referral, transplant evaluation, waitlisting, and organ receipt. Socioeconomic factors, including health insurance and access to care, explained almost 1/3 of the lower rate of transplant among black vs. white patients.

However, even after adjusting for demographic, clinical, and , blacks had a 59% lower rate of transplant than whites.

"Despite near-universal for end stage renal disease (ESRD) patients through the Medicare ESRD program, black ESRD patients are at a disadvantage to receive a ," Patzer notes. "Socioeconomic status really accounts for about 30% of this observed racial disparity in transplant access. Further research is needed to identify what may be explaining the that still exist in access to kidney transplantation."

add to favorites email to friend print save as pdf

Related Stories

Racial inequalities exist for kids with kidney disease

Nov 10, 2011

Among children with kidney disease, certain races are less likely to get kidney transplants and are more likely to die than other races, according to two studies from Emory University that were presented during the American ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments